# A Phase 1 Study to Evaluate the Relative Bioavailability of a VX-828 Tablet Formulation

> **NCT06861413** · PHASE1 · COMPLETED · sponsor: **Vertex Pharmaceuticals Incorporated** · enrollment: 68 (actual)

## Conditions studied

- Cystic Fibrosis

## Interventions

- **DRUG:** VX-828
- **DRUG:** VX-828

## Key facts

- **NCT ID:** NCT06861413
- **Lead sponsor:** Vertex Pharmaceuticals Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2025-04-01
- **Primary completion:** 2025-05-05
- **Final completion:** 2025-05-05
- **Target enrollment:** 68 (ACTUAL)
- **Last updated:** 2025-06-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06861413

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06861413, "A Phase 1 Study to Evaluate the Relative Bioavailability of a VX-828 Tablet Formulation". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06861413. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*